Ningbo Menovo Pharmaceutical Co (SHSE:603538) Marketable Securities: ¥164 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603538 Ningbo Menovo Pharmaceutical Co Ltd SHSE:603538
73 GF Score
Price ¥25.42
GF Value ¥17.68
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Ningbo Menovo Pharmaceutical Co Marketable Securities?

Ningbo Menovo Pharmaceutical Co SHSE:603538 -3.93% 73 Marketable Securities is ¥164 Mil as of Jun. 2026. GuruFocus rates SHSE:603538 with a GF Score™ of 73/100 and a GF Value™ of ¥17.68 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Ningbo Menovo Pharmaceutical Co's Marketable Securities for the quarter that ended in Jun. 2026 was ¥164 Mil.

Ningbo Menovo Pharmaceutical Co's annual Marketable Securities declined from Dec. 2023 (¥269 Mil) to Dec. 2024 (¥154 Mil) but then increased from Dec. 2024 (¥154 Mil) to Dec. 2025 (¥217 Mil).

Ningbo Menovo Pharmaceutical Co  (SHSE:603538) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Ningbo Menovo Pharmaceutical Co Marketable Securities Related Terms

Ningbo Menovo Pharmaceutical Co Marketable Securities Historical Data

* Premium members only.

The historical data trend for Ningbo Menovo Pharmaceutical Co's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ningbo Menovo Pharmaceutical Co Marketable Securities Chart

Ningbo Menovo Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 371.38 217.38 268.65 154.44 216.82

Ningbo Menovo Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 122.76 127.52 216.82 150.70 164.41
SHSE:603538
73GF Score
Ningbo Menovo Pharmaceutical Co Ltd SHSE:603538
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ningbo Menovo Pharmaceutical Co Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of ¥164 Mil mean?
Ningbo Menovo Pharmaceutical Co (SHSE:603538) has a Marketable Securities of ¥164 Mil as of Jun. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Ningbo Menovo Pharmaceutical Co and its competitors.
Is Ningbo Menovo Pharmaceutical Co's Marketable Securities too high?
Ningbo Menovo Pharmaceutical Co's current Marketable Securities is ¥164 Mil. Overall, Ningbo Menovo Pharmaceutical Co has a GF Score™ of 73/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ningbo Menovo Pharmaceutical Co's Marketable Securities compare to ZTS?
Ningbo Menovo Pharmaceutical Co's Marketable Securities of ¥164 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Drug Manufacturers company?
A good Marketable Securities depends on the Drug Manufacturers industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Ningbo Menovo Pharmaceutical Co and its competitors. Ningbo Menovo Pharmaceutical Co's current Marketable Securities is ¥164 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ningbo Menovo Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Ningbo Menovo Pharmaceutical Co (SHSE:603538) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥17.68, compared to a current price of ¥25.42 — trading 43.8% above its estimated fair value. The current Marketable Securities is ¥164 Mil. Ningbo Menovo Pharmaceutical Co's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Ningbo Menovo Pharmaceutical Co (SHSE:603538), the current Marketable Securities is ¥164 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ningbo Menovo Pharmaceutical Co (SHSE:603538) Overvalued in 2026?

Based on GuruFocus' analysis, Ningbo Menovo Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥25.42 is trading 43.8% above its estimated GF Value™ of ¥17.68. GuruFocus considers Ningbo Menovo Pharmaceutical Co to be Significantly Overvalued.

Key valuation signals for SHSE:603538:

  • Marketable Securities: ¥164 Mil
  • GF Value™: ¥17.68 vs. price of ¥25.42 (43.8% above fair value)
  • GF Score™: 73/100 with 4 warning signs

No single metric tells the full story. See the SHSE:603538 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ningbo Menovo Pharmaceutical Co Business Description

Address No.999,Yangfan Road, Room 1406, No.1, High-tech Zone, Ningbo, CHN, 315040
Ningbo Menovo Pharmaceutical Co Ltd is a China-based company is engaged in the research and development, pilot, production and sales of pharmaceutical intermediates, APIs and finished drugs. Its products line includes cardiovascular, central nervous, respiratory, anti-tumor, anti-infective, digestive system, geriatric diseases and anti-viral systems.
73GF Score

Get the complete analysis for SHSE:603538

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥25.42
Price
¥17.68
GF Value